Meeting
2020 ASCO Virtual Scientific Program
Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)—First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS).
Authors
Nick Pavlakis
Northern Cancer Institute, St Leonards, Sydney, Australia
Nick Pavlakis , David Turner Ransom , David Wyld , Katrin Marie Sjoquist , Rebecca Asher , Val Gebski , Kate Wilson , Andrew Ddembe Kiberu , Matthew E. Burge , William Macdonald , Paul Roach , David A. Pattison , Patrick Butler , Timothy Jay Price , Michael Michael , Benjamin James Lawrence , Dale L. Bailey , Simone Leyden , John Raymond Zalcberg , J. Harvey Turner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Clinical Trial Registration Number
ACTRN12615000909527
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4608)
DOI
10.1200/JCO.2020.38.15_suppl.4608
Abstract #
4608
Poster Bd #
216
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
First results for Australasian Gastrointestinal Trials Group (AGITG) control net study: Phase II study of 177Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) +/- capecitabine, temozolomide (CAPTEM) for midgut neuroendocrine tumors (mNETs).
First Author: Nick Pavlakis
Poster
2022 ASCO Annual Meeting
Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)—Final results.
First Author: Nick Pavlakis
Poster
2022 ASCO Annual Meeting
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.
First Author: Jennifer Rachel Eads
Poster
2014 Gastrointestinal Cancers Symposium
Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors.
First Author: Robert Lance Fine